16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancerX. Le, Y.Y. Elamin,M. Altan,G. Blumenschein, L.A. Byers,T. Cascone,F. Skoulidis,C. Gay, A.S. Tsao,D. Gibbons,M.V. Negrao, N. Vokes, J. Zhang,S. Heeke, J. Rotow,P.A. Jänne, B. Pellini, J. Tu, J.E. Gray,J. HeymachESMO Open（2024）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
